Accessibility Information

Users of assistive technologies such as screen readers should use the following link to activate Accessibility Mode before continuing: Learn more and Activate accessibility mode.

Butyrylcholinesterase Expression in Plants

Solicitation Number: DARPA-BAA-12-31
Agency: Other Defense Agencies
Office: Defense Advanced Research Projects Agency
Location: Contracts Management Office
  • Print

Note:

There have been modifications to this notice. You are currently viewing the original synopsis. To view the most recent modification/amendment, click here
:
DARPA-BAA-12-31
:
Presolicitation
:
Added: Feb 16, 2012 12:57 pm
DARPA is seeking innovative research proposals that will demonstrate the ability to produce a recombinant butyrylcholinesterase (rBuChE) using the Nicotiana benthamiana plant-based expression platform that has the same pharmacokinetic profile as a plasma-derived human butyrylcholinesterase (hBuChE) butyrylcholinesterase. The funding is intended to establish the technical precedence for the use of the plant platform to generate a rapid and scalable form of pre-exposure therapeutic bioscavenger against organophosphate nerve agents. Funding is for basic research only. The anticipated period of funding is for 12 months.

See attached DARPA-BAA-12-31.

Please consult the list of document viewers if you cannot open a file.

DARPA-BAA-12-31

Type:
Other (Draft RFPs/RFIs, Responses to Questions, etc..)
Label:
DARPA-BAA-12-31
Posted Date:
February 16, 2012
Description: DARPA-BAA-12-31
:
3701 North Fairfax Drive
Arlington, Virginia 22203-1714
:
Alan Magill,
Dr.